nodes	percent_of_prediction	percent_of_DWPC	metapath
Sildenafil—ABCC10—Gemcitabine—urinary bladder cancer	0.119	0.181	CbGbCtD
Sildenafil—ABCC5—Fluorouracil—urinary bladder cancer	0.102	0.155	CbGbCtD
Sildenafil—ABCC5—Cisplatin—urinary bladder cancer	0.0865	0.131	CbGbCtD
Sildenafil—ABCC10—Etoposide—urinary bladder cancer	0.085	0.129	CbGbCtD
Sildenafil—ABCC10—Doxorubicin—urinary bladder cancer	0.058	0.088	CbGbCtD
Sildenafil—ABCC10—Methotrexate—urinary bladder cancer	0.0562	0.0852	CbGbCtD
Sildenafil—ABCC4—Fluorouracil—urinary bladder cancer	0.0489	0.0743	CbGbCtD
Sildenafil—PDE5A—clitoris—urinary bladder cancer	0.03	0.346	CbGeAlD
Sildenafil—ABCC4—Methotrexate—urinary bladder cancer	0.027	0.0409	CbGbCtD
Sildenafil—CYP3A4—Thiotepa—urinary bladder cancer	0.0175	0.0266	CbGbCtD
Sildenafil—CYP2E1—Etoposide—urinary bladder cancer	0.0157	0.0238	CbGbCtD
Sildenafil—CYP3A5—Etoposide—urinary bladder cancer	0.0122	0.0185	CbGbCtD
Sildenafil—CYP2C9—Fluorouracil—urinary bladder cancer	0.00978	0.0148	CbGbCtD
Sildenafil—PDE5A—penis—urinary bladder cancer	0.00849	0.0979	CbGeAlD
Sildenafil—CYP2C9—Cisplatin—urinary bladder cancer	0.00831	0.0126	CbGbCtD
Sildenafil—CYP2D6—Doxorubicin—urinary bladder cancer	0.00509	0.00772	CbGbCtD
Sildenafil—CYP3A4—Etoposide—urinary bladder cancer	0.00475	0.0072	CbGbCtD
Sildenafil—CYP3A4—Doxorubicin—urinary bladder cancer	0.00324	0.00491	CbGbCtD
Sildenafil—CYP2C19—urine—urinary bladder cancer	0.00298	0.0344	CbGeAlD
Sildenafil—CYP2C9—urine—urinary bladder cancer	0.00231	0.0266	CbGeAlD
Sildenafil—CYP2E1—urine—urinary bladder cancer	0.00219	0.0252	CbGeAlD
Sildenafil—PDE5A—prostate gland—urinary bladder cancer	0.00203	0.0234	CbGeAlD
Sildenafil—ABCC5—prostate gland—urinary bladder cancer	0.00185	0.0214	CbGeAlD
Sildenafil—CYP3A4—urine—urinary bladder cancer	0.00176	0.0203	CbGeAlD
Sildenafil—CYP2D6—urine—urinary bladder cancer	0.00173	0.02	CbGeAlD
Sildenafil—PDE6G—lymph node—urinary bladder cancer	0.00164	0.0189	CbGeAlD
Sildenafil—ABCC10—prostate gland—urinary bladder cancer	0.00155	0.0179	CbGeAlD
Sildenafil—PDE5A—epithelium—urinary bladder cancer	0.00149	0.0172	CbGeAlD
Sildenafil—PDE5A—smooth muscle tissue—urinary bladder cancer	0.00144	0.0166	CbGeAlD
Sildenafil—PDE5A—renal system—urinary bladder cancer	0.00138	0.0159	CbGeAlD
Sildenafil—PDE5A—urethra—urinary bladder cancer	0.00136	0.0157	CbGeAlD
Sildenafil—ABCC10—seminal vesicle—urinary bladder cancer	0.00131	0.0151	CbGeAlD
Sildenafil—ABCC4—prostate gland—urinary bladder cancer	0.00129	0.0148	CbGeAlD
Sildenafil—ADORA2A—female reproductive system—urinary bladder cancer	0.00121	0.014	CbGeAlD
Sildenafil—PDE5A—female reproductive system—urinary bladder cancer	0.00111	0.0128	CbGeAlD
Sildenafil—ABCC10—renal system—urinary bladder cancer	0.00106	0.0122	CbGeAlD
Sildenafil—ABCC10—urethra—urinary bladder cancer	0.00104	0.012	CbGeAlD
Sildenafil—PDE5A—vagina—urinary bladder cancer	0.001	0.0115	CbGeAlD
Sildenafil—ABCC5—vagina—urinary bladder cancer	0.000915	0.0106	CbGeAlD
Sildenafil—ABCC4—renal system—urinary bladder cancer	0.000876	0.0101	CbGeAlD
Sildenafil—ABCC10—female reproductive system—urinary bladder cancer	0.000846	0.00976	CbGeAlD
Sildenafil—CYP3A5—prostate gland—urinary bladder cancer	0.000842	0.00972	CbGeAlD
Sildenafil—CYP2E1—prostate gland—urinary bladder cancer	0.000785	0.00906	CbGeAlD
Sildenafil—ABCC10—vagina—urinary bladder cancer	0.000765	0.00883	CbGeAlD
Sildenafil—ABCC4—female reproductive system—urinary bladder cancer	0.000702	0.0081	CbGeAlD
Sildenafil—CYP2E1—seminal vesicle—urinary bladder cancer	0.000664	0.00767	CbGeAlD
Sildenafil—PDE5A—lymph node—urinary bladder cancer	0.000647	0.00747	CbGeAlD
Sildenafil—CYP1A1—epithelium—urinary bladder cancer	0.000633	0.0073	CbGeAlD
Sildenafil—ABCC5—lymph node—urinary bladder cancer	0.000592	0.00683	CbGeAlD
Sildenafil—CYP1A1—renal system—urinary bladder cancer	0.000587	0.00677	CbGeAlD
Sildenafil—CYP1A1—urethra—urinary bladder cancer	0.000577	0.00665	CbGeAlD
Sildenafil—CYP3A5—renal system—urinary bladder cancer	0.000574	0.00662	CbGeAlD
Sildenafil—CYP2E1—renal system—urinary bladder cancer	0.000535	0.00618	CbGeAlD
Sildenafil—CYP2C19—vagina—urinary bladder cancer	0.000528	0.00609	CbGeAlD
Sildenafil—CYP2E1—urethra—urinary bladder cancer	0.000526	0.00607	CbGeAlD
Sildenafil—ABCC10—lymph node—urinary bladder cancer	0.000495	0.00571	CbGeAlD
Sildenafil—CYP1A1—female reproductive system—urinary bladder cancer	0.00047	0.00542	CbGeAlD
Sildenafil—CYP2C9—female reproductive system—urinary bladder cancer	0.000452	0.00522	CbGeAlD
Sildenafil—CYP3A4—renal system—urinary bladder cancer	0.000431	0.00497	CbGeAlD
Sildenafil—CYP2E1—female reproductive system—urinary bladder cancer	0.000429	0.00495	CbGeAlD
Sildenafil—CYP1A1—vagina—urinary bladder cancer	0.000425	0.00491	CbGeAlD
Sildenafil—CYP2D6—renal system—urinary bladder cancer	0.000424	0.00489	CbGeAlD
Sildenafil—CYP3A5—vagina—urinary bladder cancer	0.000416	0.0048	CbGeAlD
Sildenafil—ABCC4—lymph node—urinary bladder cancer	0.00041	0.00474	CbGeAlD
Sildenafil—CYP3A4—female reproductive system—urinary bladder cancer	0.000345	0.00398	CbGeAlD
Sildenafil—CYP2D6—female reproductive system—urinary bladder cancer	0.000339	0.00392	CbGeAlD
Sildenafil—CYP1A1—lymph node—urinary bladder cancer	0.000275	0.00317	CbGeAlD
Sildenafil—Diarrhoea—Fluorouracil—urinary bladder cancer	8.72e-05	0.000481	CcSEcCtD
Sildenafil—Tinnitus—Methotrexate—urinary bladder cancer	8.7e-05	0.00048	CcSEcCtD
Sildenafil—Hypoaesthesia—Epirubicin—urinary bladder cancer	8.69e-05	0.000479	CcSEcCtD
Sildenafil—Asthenia—Cisplatin—urinary bladder cancer	8.67e-05	0.000478	CcSEcCtD
Sildenafil—Pharyngitis—Epirubicin—urinary bladder cancer	8.67e-05	0.000478	CcSEcCtD
Sildenafil—Cardiac disorder—Methotrexate—urinary bladder cancer	8.66e-05	0.000478	CcSEcCtD
Sildenafil—Sweating—Doxorubicin—urinary bladder cancer	8.63e-05	0.000476	CcSEcCtD
Sildenafil—Urinary tract disorder—Epirubicin—urinary bladder cancer	8.63e-05	0.000476	CcSEcCtD
Sildenafil—Oedema peripheral—Epirubicin—urinary bladder cancer	8.61e-05	0.000474	CcSEcCtD
Sildenafil—Haematuria—Doxorubicin—urinary bladder cancer	8.58e-05	0.000473	CcSEcCtD
Sildenafil—Connective tissue disorder—Epirubicin—urinary bladder cancer	8.58e-05	0.000473	CcSEcCtD
Sildenafil—Urethral disorder—Epirubicin—urinary bladder cancer	8.56e-05	0.000472	CcSEcCtD
Sildenafil—Epistaxis—Doxorubicin—urinary bladder cancer	8.49e-05	0.000468	CcSEcCtD
Sildenafil—Angiopathy—Methotrexate—urinary bladder cancer	8.47e-05	0.000467	CcSEcCtD
Sildenafil—Sinusitis—Doxorubicin—urinary bladder cancer	8.45e-05	0.000466	CcSEcCtD
Sildenafil—Immune system disorder—Methotrexate—urinary bladder cancer	8.43e-05	0.000465	CcSEcCtD
Sildenafil—Dizziness—Fluorouracil—urinary bladder cancer	8.43e-05	0.000465	CcSEcCtD
Sildenafil—Visual impairment—Epirubicin—urinary bladder cancer	8.42e-05	0.000464	CcSEcCtD
Sildenafil—Mediastinal disorder—Methotrexate—urinary bladder cancer	8.41e-05	0.000464	CcSEcCtD
Sildenafil—Chills—Methotrexate—urinary bladder cancer	8.38e-05	0.000462	CcSEcCtD
Sildenafil—Diarrhoea—Cisplatin—urinary bladder cancer	8.27e-05	0.000456	CcSEcCtD
Sildenafil—Erythema multiforme—Epirubicin—urinary bladder cancer	8.26e-05	0.000455	CcSEcCtD
Sildenafil—Alopecia—Methotrexate—urinary bladder cancer	8.25e-05	0.000455	CcSEcCtD
Sildenafil—Vomiting—Gemcitabine—urinary bladder cancer	8.24e-05	0.000455	CcSEcCtD
Sildenafil—Mental disorder—Methotrexate—urinary bladder cancer	8.18e-05	0.000451	CcSEcCtD
Sildenafil—Rash—Gemcitabine—urinary bladder cancer	8.18e-05	0.000451	CcSEcCtD
Sildenafil—Dermatitis—Gemcitabine—urinary bladder cancer	8.17e-05	0.00045	CcSEcCtD
Sildenafil—Eye disorder—Epirubicin—urinary bladder cancer	8.16e-05	0.00045	CcSEcCtD
Sildenafil—Hypersensitivity—Etoposide—urinary bladder cancer	8.16e-05	0.00045	CcSEcCtD
Sildenafil—Tinnitus—Epirubicin—urinary bladder cancer	8.14e-05	0.000449	CcSEcCtD
Sildenafil—Erythema—Methotrexate—urinary bladder cancer	8.13e-05	0.000448	CcSEcCtD
Sildenafil—Malnutrition—Methotrexate—urinary bladder cancer	8.13e-05	0.000448	CcSEcCtD
Sildenafil—Haemoglobin—Doxorubicin—urinary bladder cancer	8.12e-05	0.000448	CcSEcCtD
Sildenafil—Headache—Gemcitabine—urinary bladder cancer	8.12e-05	0.000448	CcSEcCtD
Sildenafil—Flushing—Epirubicin—urinary bladder cancer	8.11e-05	0.000447	CcSEcCtD
Sildenafil—Cardiac disorder—Epirubicin—urinary bladder cancer	8.11e-05	0.000447	CcSEcCtD
Sildenafil—Vomiting—Fluorouracil—urinary bladder cancer	8.11e-05	0.000447	CcSEcCtD
Sildenafil—Rhinitis—Doxorubicin—urinary bladder cancer	8.1e-05	0.000447	CcSEcCtD
Sildenafil—Haemorrhage—Doxorubicin—urinary bladder cancer	8.08e-05	0.000446	CcSEcCtD
Sildenafil—Hypoaesthesia—Doxorubicin—urinary bladder cancer	8.04e-05	0.000443	CcSEcCtD
Sildenafil—Rash—Fluorouracil—urinary bladder cancer	8.04e-05	0.000443	CcSEcCtD
Sildenafil—Dermatitis—Fluorouracil—urinary bladder cancer	8.03e-05	0.000443	CcSEcCtD
Sildenafil—Pharyngitis—Doxorubicin—urinary bladder cancer	8.02e-05	0.000442	CcSEcCtD
Sildenafil—Headache—Fluorouracil—urinary bladder cancer	7.99e-05	0.00044	CcSEcCtD
Sildenafil—Urinary tract disorder—Doxorubicin—urinary bladder cancer	7.98e-05	0.00044	CcSEcCtD
Sildenafil—Oedema peripheral—Doxorubicin—urinary bladder cancer	7.96e-05	0.000439	CcSEcCtD
Sildenafil—Asthenia—Etoposide—urinary bladder cancer	7.94e-05	0.000438	CcSEcCtD
Sildenafil—Connective tissue disorder—Doxorubicin—urinary bladder cancer	7.94e-05	0.000438	CcSEcCtD
Sildenafil—Angiopathy—Epirubicin—urinary bladder cancer	7.93e-05	0.000437	CcSEcCtD
Sildenafil—Urethral disorder—Doxorubicin—urinary bladder cancer	7.92e-05	0.000437	CcSEcCtD
Sildenafil—Immune system disorder—Epirubicin—urinary bladder cancer	7.89e-05	0.000435	CcSEcCtD
Sildenafil—Mediastinal disorder—Epirubicin—urinary bladder cancer	7.87e-05	0.000434	CcSEcCtD
Sildenafil—Back pain—Methotrexate—urinary bladder cancer	7.86e-05	0.000433	CcSEcCtD
Sildenafil—Chills—Epirubicin—urinary bladder cancer	7.84e-05	0.000432	CcSEcCtD
Sildenafil—Pruritus—Etoposide—urinary bladder cancer	7.83e-05	0.000432	CcSEcCtD
Sildenafil—Arrhythmia—Epirubicin—urinary bladder cancer	7.8e-05	0.00043	CcSEcCtD
Sildenafil—Visual impairment—Doxorubicin—urinary bladder cancer	7.79e-05	0.000429	CcSEcCtD
Sildenafil—Alopecia—Epirubicin—urinary bladder cancer	7.72e-05	0.000426	CcSEcCtD
Sildenafil—Nausea—Gemcitabine—urinary bladder cancer	7.7e-05	0.000425	CcSEcCtD
Sildenafil—Vomiting—Cisplatin—urinary bladder cancer	7.68e-05	0.000424	CcSEcCtD
Sildenafil—Vision blurred—Methotrexate—urinary bladder cancer	7.66e-05	0.000422	CcSEcCtD
Sildenafil—Mental disorder—Epirubicin—urinary bladder cancer	7.65e-05	0.000422	CcSEcCtD
Sildenafil—Erythema multiforme—Doxorubicin—urinary bladder cancer	7.64e-05	0.000421	CcSEcCtD
Sildenafil—Rash—Cisplatin—urinary bladder cancer	7.62e-05	0.00042	CcSEcCtD
Sildenafil—Dermatitis—Cisplatin—urinary bladder cancer	7.61e-05	0.00042	CcSEcCtD
Sildenafil—Malnutrition—Epirubicin—urinary bladder cancer	7.6e-05	0.000419	CcSEcCtD
Sildenafil—Erythema—Epirubicin—urinary bladder cancer	7.6e-05	0.000419	CcSEcCtD
Sildenafil—Diarrhoea—Etoposide—urinary bladder cancer	7.58e-05	0.000418	CcSEcCtD
Sildenafil—Nausea—Fluorouracil—urinary bladder cancer	7.57e-05	0.000417	CcSEcCtD
Sildenafil—Eye disorder—Doxorubicin—urinary bladder cancer	7.55e-05	0.000416	CcSEcCtD
Sildenafil—Ill-defined disorder—Methotrexate—urinary bladder cancer	7.54e-05	0.000416	CcSEcCtD
Sildenafil—Tinnitus—Doxorubicin—urinary bladder cancer	7.54e-05	0.000415	CcSEcCtD
Sildenafil—Anaemia—Methotrexate—urinary bladder cancer	7.51e-05	0.000414	CcSEcCtD
Sildenafil—Flushing—Doxorubicin—urinary bladder cancer	7.5e-05	0.000414	CcSEcCtD
Sildenafil—Cardiac disorder—Doxorubicin—urinary bladder cancer	7.5e-05	0.000414	CcSEcCtD
Sildenafil—Flatulence—Epirubicin—urinary bladder cancer	7.49e-05	0.000413	CcSEcCtD
Sildenafil—Tension—Epirubicin—urinary bladder cancer	7.46e-05	0.000411	CcSEcCtD
Sildenafil—Nervousness—Epirubicin—urinary bladder cancer	7.39e-05	0.000407	CcSEcCtD
Sildenafil—Back pain—Epirubicin—urinary bladder cancer	7.36e-05	0.000406	CcSEcCtD
Sildenafil—Angiopathy—Doxorubicin—urinary bladder cancer	7.33e-05	0.000404	CcSEcCtD
Sildenafil—Malaise—Methotrexate—urinary bladder cancer	7.33e-05	0.000404	CcSEcCtD
Sildenafil—Dizziness—Etoposide—urinary bladder cancer	7.32e-05	0.000404	CcSEcCtD
Sildenafil—Immune system disorder—Doxorubicin—urinary bladder cancer	7.3e-05	0.000403	CcSEcCtD
Sildenafil—Vertigo—Methotrexate—urinary bladder cancer	7.3e-05	0.000402	CcSEcCtD
Sildenafil—Mediastinal disorder—Doxorubicin—urinary bladder cancer	7.28e-05	0.000402	CcSEcCtD
Sildenafil—Leukopenia—Methotrexate—urinary bladder cancer	7.27e-05	0.000401	CcSEcCtD
Sildenafil—Chills—Doxorubicin—urinary bladder cancer	7.25e-05	0.0004	CcSEcCtD
Sildenafil—Arrhythmia—Doxorubicin—urinary bladder cancer	7.22e-05	0.000398	CcSEcCtD
Sildenafil—Nausea—Cisplatin—urinary bladder cancer	7.18e-05	0.000396	CcSEcCtD
Sildenafil—Vision blurred—Epirubicin—urinary bladder cancer	7.17e-05	0.000395	CcSEcCtD
Sildenafil—Alopecia—Doxorubicin—urinary bladder cancer	7.14e-05	0.000394	CcSEcCtD
Sildenafil—Cough—Methotrexate—urinary bladder cancer	7.09e-05	0.000391	CcSEcCtD
Sildenafil—Mental disorder—Doxorubicin—urinary bladder cancer	7.08e-05	0.00039	CcSEcCtD
Sildenafil—Ill-defined disorder—Epirubicin—urinary bladder cancer	7.06e-05	0.000389	CcSEcCtD
Sildenafil—Convulsion—Methotrexate—urinary bladder cancer	7.04e-05	0.000388	CcSEcCtD
Sildenafil—Vomiting—Etoposide—urinary bladder cancer	7.04e-05	0.000388	CcSEcCtD
Sildenafil—Malnutrition—Doxorubicin—urinary bladder cancer	7.04e-05	0.000388	CcSEcCtD
Sildenafil—Erythema—Doxorubicin—urinary bladder cancer	7.04e-05	0.000388	CcSEcCtD
Sildenafil—Anaemia—Epirubicin—urinary bladder cancer	7.03e-05	0.000387	CcSEcCtD
Sildenafil—Agitation—Epirubicin—urinary bladder cancer	6.99e-05	0.000385	CcSEcCtD
Sildenafil—Rash—Etoposide—urinary bladder cancer	6.98e-05	0.000385	CcSEcCtD
Sildenafil—Dermatitis—Etoposide—urinary bladder cancer	6.97e-05	0.000385	CcSEcCtD
Sildenafil—Headache—Etoposide—urinary bladder cancer	6.94e-05	0.000382	CcSEcCtD
Sildenafil—Flatulence—Doxorubicin—urinary bladder cancer	6.93e-05	0.000382	CcSEcCtD
Sildenafil—Arthralgia—Methotrexate—urinary bladder cancer	6.92e-05	0.000381	CcSEcCtD
Sildenafil—Chest pain—Methotrexate—urinary bladder cancer	6.92e-05	0.000381	CcSEcCtD
Sildenafil—Myalgia—Methotrexate—urinary bladder cancer	6.92e-05	0.000381	CcSEcCtD
Sildenafil—Tension—Doxorubicin—urinary bladder cancer	6.9e-05	0.000381	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	6.87e-05	0.000379	CcSEcCtD
Sildenafil—Malaise—Epirubicin—urinary bladder cancer	6.86e-05	0.000378	CcSEcCtD
Sildenafil—Discomfort—Methotrexate—urinary bladder cancer	6.83e-05	0.000377	CcSEcCtD
Sildenafil—Nervousness—Doxorubicin—urinary bladder cancer	6.83e-05	0.000377	CcSEcCtD
Sildenafil—Vertigo—Epirubicin—urinary bladder cancer	6.83e-05	0.000377	CcSEcCtD
Sildenafil—Syncope—Epirubicin—urinary bladder cancer	6.82e-05	0.000376	CcSEcCtD
Sildenafil—Leukopenia—Epirubicin—urinary bladder cancer	6.81e-05	0.000375	CcSEcCtD
Sildenafil—Back pain—Doxorubicin—urinary bladder cancer	6.81e-05	0.000375	CcSEcCtD
Sildenafil—Palpitations—Epirubicin—urinary bladder cancer	6.72e-05	0.00037	CcSEcCtD
Sildenafil—Loss of consciousness—Epirubicin—urinary bladder cancer	6.68e-05	0.000368	CcSEcCtD
Sildenafil—Cough—Epirubicin—urinary bladder cancer	6.64e-05	0.000366	CcSEcCtD
Sildenafil—Vision blurred—Doxorubicin—urinary bladder cancer	6.63e-05	0.000366	CcSEcCtD
Sildenafil—Convulsion—Epirubicin—urinary bladder cancer	6.59e-05	0.000363	CcSEcCtD
Sildenafil—Infection—Methotrexate—urinary bladder cancer	6.59e-05	0.000363	CcSEcCtD
Sildenafil—Nausea—Etoposide—urinary bladder cancer	6.58e-05	0.000363	CcSEcCtD
Sildenafil—Hypertension—Epirubicin—urinary bladder cancer	6.57e-05	0.000362	CcSEcCtD
Sildenafil—Ill-defined disorder—Doxorubicin—urinary bladder cancer	6.53e-05	0.00036	CcSEcCtD
Sildenafil—Nervous system disorder—Methotrexate—urinary bladder cancer	6.5e-05	0.000359	CcSEcCtD
Sildenafil—Anaemia—Doxorubicin—urinary bladder cancer	6.5e-05	0.000359	CcSEcCtD
Sildenafil—Arthralgia—Epirubicin—urinary bladder cancer	6.47e-05	0.000357	CcSEcCtD
Sildenafil—Chest pain—Epirubicin—urinary bladder cancer	6.47e-05	0.000357	CcSEcCtD
Sildenafil—Myalgia—Epirubicin—urinary bladder cancer	6.47e-05	0.000357	CcSEcCtD
Sildenafil—Agitation—Doxorubicin—urinary bladder cancer	6.47e-05	0.000356	CcSEcCtD
Sildenafil—Anxiety—Epirubicin—urinary bladder cancer	6.45e-05	0.000356	CcSEcCtD
Sildenafil—Skin disorder—Methotrexate—urinary bladder cancer	6.44e-05	0.000355	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	6.43e-05	0.000354	CcSEcCtD
Sildenafil—Hyperhidrosis—Methotrexate—urinary bladder cancer	6.41e-05	0.000353	CcSEcCtD
Sildenafil—Discomfort—Epirubicin—urinary bladder cancer	6.4e-05	0.000353	CcSEcCtD
Sildenafil—Malaise—Doxorubicin—urinary bladder cancer	6.35e-05	0.00035	CcSEcCtD
Sildenafil—Dry mouth—Epirubicin—urinary bladder cancer	6.33e-05	0.000349	CcSEcCtD
Sildenafil—Vertigo—Doxorubicin—urinary bladder cancer	6.32e-05	0.000349	CcSEcCtD
Sildenafil—Anorexia—Methotrexate—urinary bladder cancer	6.32e-05	0.000349	CcSEcCtD
Sildenafil—Syncope—Doxorubicin—urinary bladder cancer	6.31e-05	0.000348	CcSEcCtD
Sildenafil—Leukopenia—Doxorubicin—urinary bladder cancer	6.3e-05	0.000347	CcSEcCtD
Sildenafil—Palpitations—Doxorubicin—urinary bladder cancer	6.22e-05	0.000343	CcSEcCtD
Sildenafil—Oedema—Epirubicin—urinary bladder cancer	6.21e-05	0.000342	CcSEcCtD
Sildenafil—Hypotension—Methotrexate—urinary bladder cancer	6.2e-05	0.000342	CcSEcCtD
Sildenafil—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.18e-05	0.000341	CcSEcCtD
Sildenafil—Infection—Epirubicin—urinary bladder cancer	6.17e-05	0.00034	CcSEcCtD
Sildenafil—Cough—Doxorubicin—urinary bladder cancer	6.14e-05	0.000339	CcSEcCtD
Sildenafil—Shock—Epirubicin—urinary bladder cancer	6.11e-05	0.000337	CcSEcCtD
Sildenafil—Convulsion—Doxorubicin—urinary bladder cancer	6.1e-05	0.000336	CcSEcCtD
Sildenafil—Nervous system disorder—Epirubicin—urinary bladder cancer	6.09e-05	0.000336	CcSEcCtD
Sildenafil—Hypertension—Doxorubicin—urinary bladder cancer	6.07e-05	0.000335	CcSEcCtD
Sildenafil—Tachycardia—Epirubicin—urinary bladder cancer	6.06e-05	0.000334	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.04e-05	0.000333	CcSEcCtD
Sildenafil—Skin disorder—Epirubicin—urinary bladder cancer	6.03e-05	0.000332	CcSEcCtD
Sildenafil—Hyperhidrosis—Epirubicin—urinary bladder cancer	6e-05	0.000331	CcSEcCtD
Sildenafil—Insomnia—Methotrexate—urinary bladder cancer	6e-05	0.000331	CcSEcCtD
Sildenafil—Chest pain—Doxorubicin—urinary bladder cancer	5.99e-05	0.00033	CcSEcCtD
Sildenafil—Arthralgia—Doxorubicin—urinary bladder cancer	5.99e-05	0.00033	CcSEcCtD
Sildenafil—Myalgia—Doxorubicin—urinary bladder cancer	5.99e-05	0.00033	CcSEcCtD
Sildenafil—Anxiety—Doxorubicin—urinary bladder cancer	5.97e-05	0.000329	CcSEcCtD
Sildenafil—Paraesthesia—Methotrexate—urinary bladder cancer	5.95e-05	0.000328	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	5.95e-05	0.000328	CcSEcCtD
Sildenafil—Discomfort—Doxorubicin—urinary bladder cancer	5.92e-05	0.000326	CcSEcCtD
Sildenafil—Anorexia—Epirubicin—urinary bladder cancer	5.92e-05	0.000326	CcSEcCtD
Sildenafil—Dyspnoea—Methotrexate—urinary bladder cancer	5.91e-05	0.000326	CcSEcCtD
Sildenafil—Somnolence—Methotrexate—urinary bladder cancer	5.9e-05	0.000325	CcSEcCtD
Sildenafil—Dry mouth—Doxorubicin—urinary bladder cancer	5.86e-05	0.000323	CcSEcCtD
Sildenafil—Dyspepsia—Methotrexate—urinary bladder cancer	5.84e-05	0.000322	CcSEcCtD
Sildenafil—Hypotension—Epirubicin—urinary bladder cancer	5.8e-05	0.00032	CcSEcCtD
Sildenafil—Decreased appetite—Methotrexate—urinary bladder cancer	5.76e-05	0.000318	CcSEcCtD
Sildenafil—Oedema—Doxorubicin—urinary bladder cancer	5.74e-05	0.000317	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.73e-05	0.000316	CcSEcCtD
Sildenafil—Fatigue—Methotrexate—urinary bladder cancer	5.72e-05	0.000315	CcSEcCtD
Sildenafil—Infection—Doxorubicin—urinary bladder cancer	5.7e-05	0.000315	CcSEcCtD
Sildenafil—Pain—Methotrexate—urinary bladder cancer	5.67e-05	0.000313	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.65e-05	0.000312	CcSEcCtD
Sildenafil—Shock—Doxorubicin—urinary bladder cancer	5.65e-05	0.000311	CcSEcCtD
Sildenafil—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.63e-05	0.00031	CcSEcCtD
Sildenafil—Insomnia—Epirubicin—urinary bladder cancer	5.61e-05	0.000309	CcSEcCtD
Sildenafil—Tachycardia—Doxorubicin—urinary bladder cancer	5.6e-05	0.000309	CcSEcCtD
Sildenafil—Skin disorder—Doxorubicin—urinary bladder cancer	5.58e-05	0.000308	CcSEcCtD
Sildenafil—Paraesthesia—Epirubicin—urinary bladder cancer	5.57e-05	0.000307	CcSEcCtD
Sildenafil—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.55e-05	0.000306	CcSEcCtD
Sildenafil—Dyspnoea—Epirubicin—urinary bladder cancer	5.53e-05	0.000305	CcSEcCtD
Sildenafil—Somnolence—Epirubicin—urinary bladder cancer	5.52e-05	0.000304	CcSEcCtD
Sildenafil—Anorexia—Doxorubicin—urinary bladder cancer	5.47e-05	0.000302	CcSEcCtD
Sildenafil—Feeling abnormal—Methotrexate—urinary bladder cancer	5.46e-05	0.000301	CcSEcCtD
Sildenafil—Dyspepsia—Epirubicin—urinary bladder cancer	5.46e-05	0.000301	CcSEcCtD
Sildenafil—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.42e-05	0.000299	CcSEcCtD
Sildenafil—Decreased appetite—Epirubicin—urinary bladder cancer	5.39e-05	0.000297	CcSEcCtD
Sildenafil—Hypotension—Doxorubicin—urinary bladder cancer	5.37e-05	0.000296	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.36e-05	0.000295	CcSEcCtD
Sildenafil—Fatigue—Epirubicin—urinary bladder cancer	5.35e-05	0.000295	CcSEcCtD
Sildenafil—Pain—Epirubicin—urinary bladder cancer	5.31e-05	0.000293	CcSEcCtD
Sildenafil—Constipation—Epirubicin—urinary bladder cancer	5.31e-05	0.000293	CcSEcCtD
Sildenafil—Urticaria—Methotrexate—urinary bladder cancer	5.27e-05	0.00029	CcSEcCtD
Sildenafil—Abdominal pain—Methotrexate—urinary bladder cancer	5.24e-05	0.000289	CcSEcCtD
Sildenafil—Body temperature increased—Methotrexate—urinary bladder cancer	5.24e-05	0.000289	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.23e-05	0.000288	CcSEcCtD
Sildenafil—Insomnia—Doxorubicin—urinary bladder cancer	5.19e-05	0.000286	CcSEcCtD
Sildenafil—Paraesthesia—Doxorubicin—urinary bladder cancer	5.16e-05	0.000284	CcSEcCtD
Sildenafil—Dyspnoea—Doxorubicin—urinary bladder cancer	5.12e-05	0.000282	CcSEcCtD
Sildenafil—Feeling abnormal—Epirubicin—urinary bladder cancer	5.11e-05	0.000282	CcSEcCtD
Sildenafil—Somnolence—Doxorubicin—urinary bladder cancer	5.11e-05	0.000281	CcSEcCtD
Sildenafil—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.07e-05	0.00028	CcSEcCtD
Sildenafil—Dyspepsia—Doxorubicin—urinary bladder cancer	5.05e-05	0.000279	CcSEcCtD
Sildenafil—Decreased appetite—Doxorubicin—urinary bladder cancer	4.99e-05	0.000275	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.96e-05	0.000273	CcSEcCtD
Sildenafil—Fatigue—Doxorubicin—urinary bladder cancer	4.95e-05	0.000273	CcSEcCtD
Sildenafil—Urticaria—Epirubicin—urinary bladder cancer	4.93e-05	0.000272	CcSEcCtD
Sildenafil—Constipation—Doxorubicin—urinary bladder cancer	4.91e-05	0.000271	CcSEcCtD
Sildenafil—Pain—Doxorubicin—urinary bladder cancer	4.91e-05	0.000271	CcSEcCtD
Sildenafil—Abdominal pain—Epirubicin—urinary bladder cancer	4.91e-05	0.00027	CcSEcCtD
Sildenafil—Body temperature increased—Epirubicin—urinary bladder cancer	4.91e-05	0.00027	CcSEcCtD
Sildenafil—Hypersensitivity—Methotrexate—urinary bladder cancer	4.89e-05	0.000269	CcSEcCtD
Sildenafil—Asthenia—Methotrexate—urinary bladder cancer	4.76e-05	0.000262	CcSEcCtD
Sildenafil—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.73e-05	0.000261	CcSEcCtD
Sildenafil—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.7e-05	0.000259	CcSEcCtD
Sildenafil—Pruritus—Methotrexate—urinary bladder cancer	4.69e-05	0.000259	CcSEcCtD
Sildenafil—Hypersensitivity—Epirubicin—urinary bladder cancer	4.57e-05	0.000252	CcSEcCtD
Sildenafil—Urticaria—Doxorubicin—urinary bladder cancer	4.56e-05	0.000252	CcSEcCtD
Sildenafil—Body temperature increased—Doxorubicin—urinary bladder cancer	4.54e-05	0.00025	CcSEcCtD
Sildenafil—Abdominal pain—Doxorubicin—urinary bladder cancer	4.54e-05	0.00025	CcSEcCtD
Sildenafil—Diarrhoea—Methotrexate—urinary bladder cancer	4.54e-05	0.00025	CcSEcCtD
Sildenafil—Asthenia—Epirubicin—urinary bladder cancer	4.45e-05	0.000245	CcSEcCtD
Sildenafil—Pruritus—Epirubicin—urinary bladder cancer	4.39e-05	0.000242	CcSEcCtD
Sildenafil—Dizziness—Methotrexate—urinary bladder cancer	4.39e-05	0.000242	CcSEcCtD
Sildenafil—Diarrhoea—Epirubicin—urinary bladder cancer	4.25e-05	0.000234	CcSEcCtD
Sildenafil—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.23e-05	0.000233	CcSEcCtD
Sildenafil—Vomiting—Methotrexate—urinary bladder cancer	4.22e-05	0.000232	CcSEcCtD
Sildenafil—Rash—Methotrexate—urinary bladder cancer	4.18e-05	0.000231	CcSEcCtD
Sildenafil—Dermatitis—Methotrexate—urinary bladder cancer	4.18e-05	0.00023	CcSEcCtD
Sildenafil—Headache—Methotrexate—urinary bladder cancer	4.15e-05	0.000229	CcSEcCtD
Sildenafil—Asthenia—Doxorubicin—urinary bladder cancer	4.12e-05	0.000227	CcSEcCtD
Sildenafil—Dizziness—Epirubicin—urinary bladder cancer	4.1e-05	0.000226	CcSEcCtD
Sildenafil—Pruritus—Doxorubicin—urinary bladder cancer	4.06e-05	0.000224	CcSEcCtD
Sildenafil—Vomiting—Epirubicin—urinary bladder cancer	3.95e-05	0.000218	CcSEcCtD
Sildenafil—Nausea—Methotrexate—urinary bladder cancer	3.94e-05	0.000217	CcSEcCtD
Sildenafil—Diarrhoea—Doxorubicin—urinary bladder cancer	3.93e-05	0.000217	CcSEcCtD
Sildenafil—Rash—Epirubicin—urinary bladder cancer	3.91e-05	0.000216	CcSEcCtD
Sildenafil—Dermatitis—Epirubicin—urinary bladder cancer	3.91e-05	0.000216	CcSEcCtD
Sildenafil—Headache—Epirubicin—urinary bladder cancer	3.89e-05	0.000214	CcSEcCtD
Sildenafil—Dizziness—Doxorubicin—urinary bladder cancer	3.8e-05	0.000209	CcSEcCtD
Sildenafil—Nausea—Epirubicin—urinary bladder cancer	3.69e-05	0.000203	CcSEcCtD
Sildenafil—Vomiting—Doxorubicin—urinary bladder cancer	3.65e-05	0.000201	CcSEcCtD
Sildenafil—Rash—Doxorubicin—urinary bladder cancer	3.62e-05	0.0002	CcSEcCtD
Sildenafil—Dermatitis—Doxorubicin—urinary bladder cancer	3.62e-05	0.000199	CcSEcCtD
Sildenafil—Headache—Doxorubicin—urinary bladder cancer	3.6e-05	0.000198	CcSEcCtD
Sildenafil—Nausea—Doxorubicin—urinary bladder cancer	3.41e-05	0.000188	CcSEcCtD
Sildenafil—CYP2E1—Metabolism—TYMP—urinary bladder cancer	1.97e-05	0.000271	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	1.97e-05	0.000271	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—ENO2—urinary bladder cancer	1.97e-05	0.000271	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—TYMP—urinary bladder cancer	1.97e-05	0.000271	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	1.96e-05	0.000268	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—IL2—urinary bladder cancer	1.96e-05	0.000268	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—EP300—urinary bladder cancer	1.94e-05	0.000266	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	1.91e-05	0.000262	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—CCND1—urinary bladder cancer	1.91e-05	0.000262	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	1.91e-05	0.000262	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	1.9e-05	0.000261	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.89e-05	0.000259	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—SRC—urinary bladder cancer	1.88e-05	0.000259	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.87e-05	0.000256	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—TYMP—urinary bladder cancer	1.86e-05	0.000256	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	1.85e-05	0.000255	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—MMP9—urinary bladder cancer	1.85e-05	0.000254	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—CDKN1A—urinary bladder cancer	1.84e-05	0.000253	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—PTEN—urinary bladder cancer	1.84e-05	0.000253	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.8e-05	0.000247	CbGpPWpGaD
Sildenafil—ABCC5—Disease—RHOA—urinary bladder cancer	1.8e-05	0.000247	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.79e-05	0.000245	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—NAT2—urinary bladder cancer	1.79e-05	0.000245	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.78e-05	0.000245	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—NAT2—urinary bladder cancer	1.78e-05	0.000245	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—S100B—urinary bladder cancer	1.78e-05	0.000244	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—EP300—urinary bladder cancer	1.75e-05	0.000241	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.75e-05	0.000241	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.74e-05	0.000239	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—PPARG—urinary bladder cancer	1.73e-05	0.000238	CbGpPWpGaD
Sildenafil—PDE6G—Disease—HRAS—urinary bladder cancer	1.71e-05	0.000235	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—SRC—urinary bladder cancer	1.71e-05	0.000234	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—RHOA—urinary bladder cancer	1.68e-05	0.000231	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—NAT2—urinary bladder cancer	1.68e-05	0.000231	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—CREBBP—urinary bladder cancer	1.66e-05	0.000228	CbGpPWpGaD
Sildenafil—ABCC5—Disease—ERBB2—urinary bladder cancer	1.66e-05	0.000228	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.63e-05	0.000224	CbGpPWpGaD
Sildenafil—ABCC5—Disease—PTGS2—urinary bladder cancer	1.63e-05	0.000223	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—NCOR1—urinary bladder cancer	1.6e-05	0.000219	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.6e-05	0.000219	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—NQO1—urinary bladder cancer	1.59e-05	0.000218	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—KRAS—urinary bladder cancer	1.56e-05	0.000214	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—IL2—urinary bladder cancer	1.56e-05	0.000214	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—RRM2—urinary bladder cancer	1.54e-05	0.000212	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—RRM2—urinary bladder cancer	1.54e-05	0.000211	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—MYC—urinary bladder cancer	1.53e-05	0.00021	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.53e-05	0.00021	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—TYMP—urinary bladder cancer	1.52e-05	0.000209	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.51e-05	0.000208	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.51e-05	0.000208	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—EGFR—urinary bladder cancer	1.5e-05	0.000205	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.48e-05	0.000203	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.46e-05	0.000201	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—RRM2—urinary bladder cancer	1.45e-05	0.0002	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—ENO2—urinary bladder cancer	1.43e-05	0.000196	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	1.43e-05	0.000196	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	1.42e-05	0.000196	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—ENO2—urinary bladder cancer	1.42e-05	0.000196	CbGpPWpGaD
Sildenafil—ABCC5—Disease—CDKN1A—urinary bladder cancer	1.42e-05	0.000195	CbGpPWpGaD
Sildenafil—ABCC5—Disease—PTEN—urinary bladder cancer	1.42e-05	0.000195	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—IL2—urinary bladder cancer	1.41e-05	0.000194	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—KRAS—urinary bladder cancer	1.41e-05	0.000194	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—TERT—urinary bladder cancer	1.41e-05	0.000193	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.4e-05	0.000192	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.39e-05	0.000191	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.39e-05	0.000191	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—TP53—urinary bladder cancer	1.39e-05	0.00019	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	1.38e-05	0.00019	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.38e-05	0.00019	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	1.38e-05	0.00019	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—NAT2—urinary bladder cancer	1.38e-05	0.000189	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—PTGS2—urinary bladder cancer	1.36e-05	0.000187	CbGpPWpGaD
Sildenafil—ABCC5—Disease—EP300—urinary bladder cancer	1.35e-05	0.000186	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	1.35e-05	0.000185	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—ENO2—urinary bladder cancer	1.35e-05	0.000185	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.34e-05	0.000184	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.33e-05	0.000183	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—HRAS—urinary bladder cancer	1.33e-05	0.000182	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	1.32e-05	0.000182	CbGpPWpGaD
Sildenafil—ABCC5—Disease—SRC—urinary bladder cancer	1.32e-05	0.000181	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	1.31e-05	0.000179	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—FGFR3—urinary bladder cancer	1.29e-05	0.000177	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.29e-05	0.000176	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.27e-05	0.000174	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.26e-05	0.000172	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—TP53—urinary bladder cancer	1.26e-05	0.000172	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—ESR1—urinary bladder cancer	1.25e-05	0.000172	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.25e-05	0.000171	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—TYMS—urinary bladder cancer	1.23e-05	0.000169	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	1.22e-05	0.000167	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	1.22e-05	0.000167	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—HRAS—urinary bladder cancer	1.2e-05	0.000165	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.19e-05	0.000163	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—PTEN—urinary bladder cancer	1.19e-05	0.000163	CbGpPWpGaD
Sildenafil—ABCC5—Disease—MYC—urinary bladder cancer	1.18e-05	0.000162	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.18e-05	0.000161	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—GPX1—urinary bladder cancer	1.17e-05	0.00016	CbGpPWpGaD
Sildenafil—ABCC5—Disease—EGFR—urinary bladder cancer	1.15e-05	0.000158	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—NQO1—urinary bladder cancer	1.15e-05	0.000158	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.15e-05	0.000158	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.15e-05	0.000157	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	1.14e-05	0.000157	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—EP300—urinary bladder cancer	1.13e-05	0.000156	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.1e-05	0.000151	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.1e-05	0.000151	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.1e-05	0.000151	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.09e-05	0.00015	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.09e-05	0.00015	CbGpPWpGaD
Sildenafil—ABCC5—Disease—KRAS—urinary bladder cancer	1.09e-05	0.00015	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—IGF1—urinary bladder cancer	1.09e-05	0.000149	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—NQO1—urinary bladder cancer	1.08e-05	0.000149	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.08e-05	0.000149	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.08e-05	0.000148	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.08e-05	0.000148	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.07e-05	0.000147	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.05e-05	0.000145	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.05e-05	0.000144	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.02e-05	0.00014	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.01e-05	0.000139	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.01e-05	0.000139	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1e-05	0.000138	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1e-05	0.000138	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.98e-06	0.000137	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—RHOA—urinary bladder cancer	9.95e-06	0.000137	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	9.83e-06	0.000135	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	9.74e-06	0.000134	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	9.6e-06	0.000132	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.59e-06	0.000132	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	9.58e-06	0.000131	CbGpPWpGaD
Sildenafil—ABCC5—Disease—HRAS—urinary bladder cancer	9.26e-06	0.000127	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—ERBB2—urinary bladder cancer	9.21e-06	0.000126	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.18e-06	0.000126	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—TYMP—urinary bladder cancer	9.16e-06	0.000126	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	9.05e-06	0.000124	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—TYMS—urinary bladder cancer	8.92e-06	0.000123	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—TYMS—urinary bladder cancer	8.9e-06	0.000122	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—NQO1—urinary bladder cancer	8.88e-06	0.000122	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	8.82e-06	0.000121	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	8.82e-06	0.000121	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	8.8e-06	0.000121	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	8.8e-06	0.000121	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.75e-06	0.00012	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—CXCL8—urinary bladder cancer	8.73e-06	0.00012	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PPARG—urinary bladder cancer	8.73e-06	0.00012	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—HRAS—urinary bladder cancer	8.68e-06	0.000119	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.61e-06	0.000118	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—GPX1—urinary bladder cancer	8.45e-06	0.000116	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—GPX1—urinary bladder cancer	8.43e-06	0.000116	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—TYMS—urinary bladder cancer	8.41e-06	0.000115	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	8.38e-06	0.000115	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—IL2—urinary bladder cancer	8.35e-06	0.000115	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	8.32e-06	0.000114	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	8.32e-06	0.000114	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	8.29e-06	0.000114	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NAT2—urinary bladder cancer	8.28e-06	0.000114	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	8.28e-06	0.000114	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NQO1—urinary bladder cancer	8.17e-06	0.000112	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—CCND1—urinary bladder cancer	8.14e-06	0.000112	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NQO1—urinary bladder cancer	8.09e-06	0.000111	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—GPX1—urinary bladder cancer	7.96e-06	0.000109	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MMP9—urinary bladder cancer	7.9e-06	0.000108	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	7.87e-06	0.000108	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.85e-06	0.000108	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—PTEN—urinary bladder cancer	7.85e-06	0.000108	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	7.82e-06	0.000107	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	7.79e-06	0.000107	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	7.78e-06	0.000107	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.51e-06	0.000103	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—EP300—urinary bladder cancer	7.49e-06	0.000103	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	7.4e-06	0.000102	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	7.35e-06	0.000101	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—SRC—urinary bladder cancer	7.28e-06	0.0001	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.16e-06	9.84e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—RRM2—urinary bladder cancer	7.15e-06	9.82e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—TYMS—urinary bladder cancer	6.88e-06	9.45e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	6.86e-06	9.42e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.85e-06	9.4e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.81e-06	9.35e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	6.8e-06	9.34e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	6.8e-06	9.34e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	6.75e-06	9.27e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.62e-06	9.09e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.62e-06	9.09e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.53e-06	8.97e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MYC—urinary bladder cancer	6.53e-06	8.96e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GPX1—urinary bladder cancer	6.52e-06	8.95e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.42e-06	8.82e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	6.4e-06	8.78e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—EGFR—urinary bladder cancer	6.38e-06	8.76e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—TYMS—urinary bladder cancer	6.33e-06	8.69e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PPARG—urinary bladder cancer	6.32e-06	8.68e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PPARG—urinary bladder cancer	6.31e-06	8.66e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—TYMS—urinary bladder cancer	6.28e-06	8.62e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	6.26e-06	8.59e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	6.26e-06	8.59e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	6.2e-06	8.52e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	6.2e-06	8.52e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	6.07e-06	8.34e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	6.06e-06	8.32e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—KRAS—urinary bladder cancer	6.03e-06	8.28e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	6.01e-06	8.26e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.99e-06	8.23e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PTEN—urinary bladder cancer	5.99e-06	8.22e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PPARG—urinary bladder cancer	5.96e-06	8.18e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GPX1—urinary bladder cancer	5.94e-06	8.16e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.88e-06	8.08e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	5.83e-06	8.01e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	5.72e-06	7.86e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—EP300—urinary bladder cancer	5.71e-06	7.84e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.53e-06	7.59e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	5.48e-06	7.53e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—TP53—urinary bladder cancer	5.36e-06	7.36e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.34e-06	7.33e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—HRAS—urinary bladder cancer	5.13e-06	7.04e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	4.97e-06	6.83e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	4.96e-06	6.81e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PPARG—urinary bladder cancer	4.88e-06	6.7e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	4.69e-06	6.44e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	4.68e-06	6.43e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.49e-06	6.16e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.45e-06	6.11e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PPARG—urinary bladder cancer	4.45e-06	6.1e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PTEN—urinary bladder cancer	4.34e-06	5.95e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PTEN—urinary bladder cancer	4.33e-06	5.94e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	4.31e-06	5.92e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	4.27e-06	5.86e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.14e-06	5.68e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—EP300—urinary bladder cancer	4.14e-06	5.68e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—EP300—urinary bladder cancer	4.13e-06	5.67e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.09e-06	5.62e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.09e-06	5.62e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PTEN—urinary bladder cancer	4.09e-06	5.61e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.92e-06	5.38e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—EP300—urinary bladder cancer	3.9e-06	5.35e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.85e-06	5.28e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	3.84e-06	5.27e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.62e-06	4.96e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.53e-06	4.84e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.5e-06	4.8e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PTEN—urinary bladder cancer	3.35e-06	4.59e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—EP300—urinary bladder cancer	3.19e-06	4.38e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PTEN—urinary bladder cancer	3.08e-06	4.22e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PTEN—urinary bladder cancer	3.05e-06	4.19e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.93e-06	4.03e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.93e-06	4.03e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.91e-06	3.99e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.82e-06	3.87e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.31e-06	3.17e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.01e-06	2.76e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.92e-06	2.63e-05	CbGpPWpGaD
